Title
Towards a platform process for the manufacture of glycoconjugate vaccines for pneumococcal disease
Conference Dates
June 12 – 17, 2022
Abstract
Streptococcus pneumoniae (S. pneumoniae) is one of the leading causes of invasive bacterial disease in children where infection results in pneumonia and meningitis. The introduction of glycoconjugate vaccines for the bacterium has meant a significant reduction in cases of invasive bacterial diseases in children under the age of 5 worldwide. The current gold standard glycoconjugate vaccine for immunization is Prevenar-13. However, a currently complex and long manufacturing process involving chemical conjugation means the final cost per dose of the vaccine is high.
Please click Download on the upper right corner to see the full abstract.
Recommended Citation
Dr. Michael Sulu, Neha Patel, Dr. Emily Kay, Dr. Jon Cuccui, and Dr. Frank Baganz, "Towards a platform process for the manufacture of glycoconjugate vaccines for pneumococcal disease" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/14